scholarly journals Relationship between serum inhibitory activity for IgE and efficacy of Artemisia pollen subcutaneous immunotherapy for allergic rhinitis: a preliminary self-controlled study

2020 ◽  
Vol 16 (1) ◽  
Author(s):  
Wenping Wang ◽  
Jinshu Yin ◽  
Xueyan Wang ◽  
Tingting Ma ◽  
Tianfei Lan ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Inhibitory Activity ◽  
Controlled Study ◽  
Subcutaneous Immunotherapy ◽  
Artemisia Pollen

Effect of adjunctive sodium hyaluronate versus surfactant nasal irrigation on mucociliary clearance in allergic rhinitis: a single-blind, randomised, controlled study

2021 ◽  
pp. 1-4
Author(s):  
E Ocak ◽  
S Mulazimoglu ◽  
D Kocaoz ◽  
E Mirici ◽  
E Dagli ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Mucociliary Clearance ◽  
Isotonic Saline ◽  
Sodium Hyaluronate ◽  
Controlled Study ◽  
Control Group ◽  
Clearance Time ◽  
Nasal Irrigation ◽  
Persistent Allergic Rhinitis ◽  
Randomised Controlled

Abstract Objective To investigate the effects of nasal irrigation with sodium hyaluronate and surfactant solutions on mucociliary clearance time in patients with mild persistent allergic rhinitis. Methods A total of 120 patients diagnosed with mild persistent allergic rhinitis were enrolled in this prospective study. The patients were allocated randomly to the surfactant, sodium hyaluronate or isotonic saline (as a control) nasal irrigation group. The mucociliary clearance times and improvements in mucociliary clearance times were compared. Results Improvements in mean mucociliary clearance time were significantly greater in the surfactant and sodium hyaluronate groups than in the control group (p < 0.01). The mean post-treatment mucociliary clearance time of the surfactant group was significantly lower than that of the control (p < 0.001) and sodium hyaluronate groups (p = 0.03). Conclusion Surfactant and sodium hyaluronate nasal irrigation solutions may both be used as adjunctive treatments for allergic rhinitis. Surfactant nasal irrigation resulted in better mucociliary clearance times.

Rupatadine oral solution in children with persistent allergic rhinitis: A randomized, double-blind, placebo-controlled study

2013 ◽  
Vol 24 (2) ◽  
pp. 144-150 ◽  
Author(s):  
Paul Potter ◽  
Jorge F. Maspero ◽  
Jan Vermeulen ◽  
László Barkai ◽  
Ildikó Németh ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Oral Solution ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Persistent Allergic Rhinitis

scholarly journals Immunotherapy in Allergic Rhinitis: It’s Effect on the Immune System and Clinical Symptoms

2018 ◽  
Vol 6 (7) ◽  
pp. 1248-1252 ◽  
Author(s):  
Samaneh Kouzegaran ◽  
Mohammad Ali Zamani ◽  
Reza Faridhosseini ◽  
Houshang Rafatpanah ◽  
Abdolrahim Rezaee ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Clinical Symptoms ◽  
Nasal Congestion ◽  
Subcutaneous Immunotherapy ◽  
Positive Skin Prick Test ◽  
Tgf Beta ◽  
Positive Skin ◽  
Ifn Gamma ◽  
Clinical Criteria ◽  
Prick Test

BACKGROUND: Allergic rhinitis is one of the most common allergic diseases and characterised by sneezing, rhinorrhea, nasal congestion and nasopharyngeal itching. Subcutaneous immunotherapy (SCIT) for specific allergens is an effective treatment and induces the inhibitory effect of T regulatory lymphocytes and decreases clinical symptoms in allergic rhinitis.AIM: In this study effect of subcutaneous immunotherapy with specific allergens on clinical symptoms and T regulatory and T Helper cells cytokines, in patients with allergic rhinitis are evaluated.METHODS: In this study, 30 patients with moderate to severe allergic rhinitis according to clinical criteria and positive skin prick test for aeroallergens were selected and treated by SCIT. Clinical symptoms and T cells cytokines IL4, IL17, IFN gamma, TGF beta, GITR, FOXP3 and IL-10 (by RT-PCR) were evaluated before and one year after initiation of treatment.RESULTS: Thirty (30) patients with allergic rhinitis at age range 15-45 years old were treated by SCIT, and 23 (14 female, 9 male) patients continued the study, and 7 patients did not continue treatment. After immunotherapy, clinical symptoms decreased significantly. The specific cytokines TGF beta and IL10 levels increased and changes were statistically significant. (Respectively P = 0.013 and P = 0.05) The IL17 level was also increased, but not statistically significant. (P = 0.8) IFN gamma, IL4, GITR, FOXP3, all decreased, but the changes were not statistically significant (P > 0.05).CONCLUSION: Subcutaneous Immunotherapy for specific allergens decreases clinical symptoms in patients with allergic rhinitis and induces tolerance in T lymphocytes, especially by increasing T regulatory cells cytokines, TGF beta and IL10.

scholarly journals Subcutaneous immunotherapy induces alterations in monocytes and dendritic cells homeostasis in allergic rhinitis patients

2018 ◽  
Vol 14 (1) ◽  
Author(s):  
Letícia Sousa ◽  
Carmen Martín-Sierra ◽  
Celso Pereira ◽  
Graça Loureiro ◽  
Beatriz Tavares ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Dendritic Cells ◽  
Subcutaneous Immunotherapy

scholarly journals Recent advances in allergic rhinitis

F1000Research ◽  
2018 ◽  
Vol 7 ◽  
pp. 1333 ◽  
Author(s):  
Flavia C. L. Hoyte ◽  
Harold S. Nelson
Keyword(s):  
Allergic Rhinitis ◽  
Work Productivity ◽  
Allergen Challenge ◽  
Economic Cost ◽  
Symptomatic Treatment ◽  
The United States ◽  
Specific Ige ◽  
Subcutaneous Immunotherapy ◽  
Nasal Allergy

Allergic rhinitis affects 20 to 30% of adults in both the United States and Europe and perhaps a somewhat higher percentage of children. In addition to nasal and ocular symptoms directly related to the allergic process, interference of these symptoms with sleep leads to daytime sleepiness and impaired quality of life. Patients miss work because of symptoms but an even greater problem is interference with work productivity, or presenteeism, which has been reported to be the biggest contributor to the total economic cost of allergic rhinitis. There has been increasing awareness that many patients with either seasonal or perennial symptoms but negative skin and in vitro tests for allergen sensitivity have local nasal allergy, diagnosable by the presence of allergen-specific IgE in their nasal secretions or a positive nasal allergen challenge or both. The pharmaceutical management of allergic rhinitis rests on symptomatic treatment with antihistamines that perhaps are more effectively administered intranasally than orally and intranasal corticosteroids. Allergen immunotherapy is very effective, even for local allergic rhinitis, and the shortcomings of subcutaneous immunotherapy of inconvenience and safety are reduced by the introduction of sublingual immunotherapy (SLIT). Use of the latter is currently somewhat limited by the lack of appropriate dosing information for SLIT liquids and the limited number of allergens for which SLIT tablets are available.

Sign in / Sign up

Export Citation Format

Share Document